Lupin – Recall of metformin extended-release

- On June 10, 2020, Lupin announced a voluntary, consumer-level recall of one lot of metformin extended-release (ER) tablets due to the detection of N-nitrosodimethylamine (NDMA) impurities.

- NDMA is classified as a probable human carcinogen based on results from laboratory tests. NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables.

Product Description	NDC#	Lot# (Expiration Date)
Metformin ER 500 mg tablets	68180-336-07	G901203 (12/2020)

- Metformin ER tablets are indicated as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes mellitus.

- Patients who have the recalled metformin ER should continue taking it until a doctor or pharmacist gives them a replacement or a different treatment option.

- Health care professionals should continue to prescribe metformin when clinically appropriate. FDA testing has not shown NDMA in immediate release (IR) metformin products (the most commonly prescribed type of metformin).

- Anyone with an existing inventory of the recalled product should stop distribution and quarantine the product immediately.

- The FDA continues to evaluate the safety of metformin and will provide more information as it becomes available. Updates can be found here. Commonly asked questions about NDMA impurities in metformin products can be found here.

- Contact Inmar by phone at **1-855-532-1856** for more information about this recall.